Basiliximab for the therapy of acute T cell–mediated rejection in kidney transplant recipient with BK virus infection: A case report

A 66-year-old Chinese man underwent a deceased donor kidney transplantation. Induction-immunosuppressive protocol consisted of basiliximab (BAS) and methyl prednisolone (MP), followed by maintenance immunosuppression with cyclosporin (CsA), mycophenolate mofetil (MMF), and prednisone (PED). The patient’s post-transplantation course was almost uneventful, and the graft was functioning well [serum creatinine (Scr) 2.15 mg/dL]. The MMF and CsA doses were decreased 1-month post-operative as the BK virus activation was serologically positive. His Scr was elevated to 2.45 mg/dL 45 days after the transplant. A graft biopsy showed BKV nephropathy (BKVN) and acute T cell–mediated rejection (TCMR) Banff grade IIA (I2, t2, ptc2, v1, c4d1, g0, and SV40 positive). The conventional anti-rejection therapy could deteriorate his BKVN, therefore, we administered BAS to eliminate activated graft-infiltrating T cells and combined with low-dose steroid. He responded well to the therapy after two doses of BAS were given, and the kidney graft status has been stable (recent Scr 2.1 mg/dL).

[1]  M. Stegall,et al.  The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody‐mediated rejection , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  P. Randhawa,et al.  BK polyomavirus in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice , 2019, Clinical transplantation.

[3]  A. Webster,et al.  Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. , 2017, The Cochrane database of systematic reviews.

[4]  M. Onodera,et al.  Basiliximab treatment for steroid‐resistant rejection in pediatric patients following liver transplantation for acute liver failure , 2014, Pediatric transplantation.

[5]  Dong-ping Wang,et al.  Steroid-resistant acute rejection after cadaveric liver transplantation: experience from one single center. , 2014, Clinics and research in hepatology and gastroenterology.

[6]  K. Hasegawa,et al.  A single-center experience of the use of interleukin-2 receptor antagonists for various situations in liver transplant recipients. , 2014, Transplantation proceedings.

[7]  C. Ponticelli.  Basiliximab: efficacy and safety evaluation in kidney transplantation , 2014, Expert opinion on drug safety.

[8]  K. Hasegawa,et al.  Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis. , 2011, Bioscience trends.

[9]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[10]  SUPPORTING TABLES,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Y. Ogawa,et al.  Successful rescue of late‐onset acute T‐cell mediated rejection with anti‐CD25 antibody: a case report , 2009, Clinical transplantation.

[12]  Y. Ogawa,et al.  Severe acute‐hybrid rejection occurring nine months after kidney transplantation: a report of rescue by orchestration of antirejection therapies , 2008 .

[13]  B. Portmann,et al.  Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. , 2005, Transplantation Proceedings.

[14]  M. Rela,et al.  Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience1 , 2003, Transplantation.

[15]  W. Lye,et al.  Biopsy-proven resolution of steroid-resistant acute rejection with basiliximab therapy in a renal allograft recipient. , 2001, Transplantation proceedings.

[16]  H. Wolters,et al.  Basiliximab in the therapy of acute rejection after organ transplantation. , 2001, Transplantation proceedings.

[17]  M. Giral,et al.  Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. , 1990, The New England journal of medicine.

[18]  J. Castroagudín,et al.  [Basiliximab in the treatment of acute steroid-resistant rejection after liver transplantation]. , 2012, Gastroenterology & hepatology.

[19]  D. C. Henckel,et al.  Case report. , 1995, Journal.